“Enara” is derived from an Arabic word that means illumination, enlightenment and bringing light into darkness.
The company believes this new name more closely illustrates Enara Bio’s mission as a science-led organization exploring the genomic dark matter as a source of novel cancer-specific T-cell antigens. The rebrand also recognises the company’s new TCR research capabilities, including programs that could enable immune recognition of a broad range of tumour cell types in an HLA-independent fashion, and thus offer broadly applicable T-cell therapies. By building discovery efforts on both sides of the T-cell/cancer-cell interface (the “immune synapse”), Enara Bio is building a pipeline of cancer immunotherapies for broad patient populations.
The company was founded as Ervaxx Ltd. in late 2016 with an initial focus on the development of therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV) DNA sequences. Since then, and based on breakthrough science coming from both internally generated and in-licensed insights, Enara Bio has broadened its horizons to include TCR-based immunotherapies targeting an extended cancer-associated antigenic repertoire derived from the entire genomic dark matter, termed Dark Antigens™.